true, a win for traders,yes,and longs as well, but the "certainty" of a revenue stream without sacrificing too much on copax would allow the company to direct its efforts on drugs#3,4 etc...
That's what I thought last year and the company thought otherwise.
I still don't understand why MNTA had the offering. The only plausible answer is that it thought TLov approval was soon. If they thought that in 2010, why would they not think that now (unless they have found out something in discovery).
I will continue to think that last year's offering was a mistake.
Market Data 
Markets 
AI
